Determination of sumatriptan in human plasma using liquid chromatography-mass spectrometry for pharmacokinetic study in healthy Korean volunteers

Rapid and naked-eye colorimetric detection of ultra trace sumatriptan in drinking water, saliva, and human urine samples based on the aggregation of gold nanoparticles

In this study, the determination of sumatriptan (SUM) was performed using a simple, rapid, and precise colorimetric method based on the surface plasmon resonance (SPR) feature of gold nanoparticles (AuNPs). By adding SUM, the aggregation was observed in AuNPs with red-to-blue color shifts. The size distribution of NPs was estimated before and after adding SUM via dynamic light scattering (DLS), which was found to be 15.34 and 97.45 nm, respectively. Characterization of AuNPs, SUM, and AuNPs in combination with SUM was investigated using transmission electron microscopy (TEM) and Fourier transform infrared spectroscopy (FTIR). Examining the effect of pH, the volume of buffer, the concentration of AuNPs, interaction time, and ionic strength revealed that their optimal values were 6, 100 μL, 5 μM, 14 min, and 12 μg L-1, respectively. The suggested method was able to determine the amount of SUM in a linear range of 10 to 250 μg L-1 with a limit of detection (LOD) and limit of quantification (LOQ) of 0.392 and 1.03 μg L-1, respectively. This approach was successfully applied to determine SUM in drinking water, saliva, and human urine samples with relative standard deviations (RSD) lower than 0.03%, 0.3%, and 1.0%, respectively.

Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling

Sumatriptan was introduced in 1983, as the first of the triptans, selective 5‐hydroxytryptamine (5‐HT_1B/1D) receptor agonists, to treat moderate to severe migraine. Migraine predominates in females. Although there have been reports of sex differences in migraine‐associated features and pharmacokinetics (PKs) of some triptans, sex differences in the PKs of oral sumatriptan have never been evaluated in Korean. We conducted this study of oral sumatriptan to assess the sex differences in Korean population. Thirty‐eight healthy Korean subjects who participated in two separate clinical studies receiving a single oral dose of 50 mg sumatriptan with the same protocols were included in this analysis. A total of 532 sumatriptan concentration observations were used for a population PK modeling. Validation of final population PK model of sumatriptan was performed using bootstrap and visual predictive check. The PK profile of oral sumatriptan was adequately described by a one‐compartmental model with combined transit compartment model and a first‐order absorption. The covariate analysis showed that the clearance of oral sumatriptan was significantly higher in males than in females (male: 444 L/h, female: 281 L/h). Our results showed that there were sex differences in the clearance of oral sumatriptan. These results encourage further studies to establish the sumatriptan pharmacokinetic–pharmacodynamic model considering sex‐related PK differences, which may help to determine optimal dosing regimens for effective treatment of migraine in males and females. Clinical trial registration: CRIS Registration No. KCT0001784.